The assessment of data mining for the prediction of therapeutic outcome in 3719 Egyptian patients with chronic hepatitis C

Clinics and Research in Hepatology and Gastroenterology

Volumn 37, Issue 3, 2013, Pages 254-261

  Zayed, Naglaa ^a   Awad, Abu Bakr ^b   El Akel, Wafaa ^a   Doss, Wahid ^a,d   Awad, Tahany ^a,c   Radwan, Amr ^e   Mabrouk, Mahasen ^a  

^a CAIRO UNIVERSITY   (Egypt)

^b Cairo University   (Egypt)

^c University of Copenhagen   (Denmark)

^d MINISTRY OF HEALTH   (Egypt)

^e ACADEMY OF SCIENTIFIC RESEARCH AND TECHNOLOGY OF THE ARAB REPUBLIC OF EGYPT   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN;

ADULT; ALGORITHM; ANTIVIRAL THERAPY; ARTICLE; DATA MINING; DECISION TREE; FEMALE; FOLLOW UP; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; INTENTION TO TREAT ANALYSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ALPHA-FETOPROTEINS; ANTIVIRAL AGENTS; DECISION TREES; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; MALE; MULTIVARIATE ANALYSIS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; SEX FACTORS;

EID: 84878918063     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2012.09.005     Document Type: Article

References (47)

1. El-Zanaty F., Way A. Egypt demographic and health survey 2008 2009, Ministry of Health, El-Zanaty and Associates, and Macro International, Cairo, Egypt.
2. Abdel-Aziz F., Habib M., Mohamed M.K., Abdel-Hamid M., Gamil F., Madkour S., et al. Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence. Hepatology 2000, 32:111-115.
3. Esmat G., Abouzied A.M., Abdel-Aziz F., Strickland T. Subjects with chronic hepatitis C and genotype 4 have a similarly effective response to standard or pegylated interferon in combination with ribavirin. Hepatology 2003, 38:324A. [Abstract].
4. El Zayadi A.R., Attia M., Barakat E.M., et al. Response of hepatitis C genotype-4 naive patients to 24weeks of peginterferon-a2b/ribavirin or induction-dose interferon a2b/ribavirin/amantadine: a non-randomized controlled study. Am J Gastroenterol 2005, 100(11):2447-2452.
5. Derbala M.F., El Dweik N.Z., Al Kaabi S.R., et al. Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy. J Viral Hepat 2008, 15(8):591-599. 10.1111/j.1365-2893.2008.00988.x.
6. El Makhzangy H., Esmat G., Said M., et al. Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4. J Med Virol 2009, 81(9):1576-1583.
7. Moucari R., Ripault M.P., Martinot-Peignoux M., et al. Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4. Gut 2009, 58(12):1662-1669. [Epub 2009 Aug 10].
8. Rallón N.I., Naggie S., Benito J.M., et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS 2010, 24(8):F23-F29.
9. Asahina Y., Izumi N., Hirayama I., et al. Potential relevance of cytoplasmic viral sensors and related regulators involving innate immunity in antiviral response. Gastroenterology 2008, 134(5):1396-1405.
10. Shirakawa H., Matsumoto A., Joshita S., et al. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology 2008, 48(6):1753-1760.
11. Kurosaki M., Sakamoto N., Iwasaki M., et al. Pretreatment prediction of response to peginterferon plus ribavirintherapy in genotype 1 chronic hepatitis C using data mining analysis. J Gastroenterol 2011, 46(3):401-409.
12. Breiman L., Friedman J.H., Olshen R.A., Sotne C.J. Classification and regression trees 1984, Wadsworth, Belmont, California.
13. Quinlan J. C4.5: programs for machine learning 1993, Morgan Kaufmann, San Mateo, CA.
14. LeBlanc M., Crowley J. A review of tree-based prognostic models. Cancer Treat Res 1995, 75:113-124.
15. Kurosaki M., Matsunaga K., Hirayama I., et al. A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis. Hepatol Res 2010, 40(4):251-260.
16. Garzotto M., Beer T.M., Hudson R.G., et al. Improved detection of prostate cancer using classification and regression tree analysis. J Clin Oncol 2005, 23(19):4322-4329. [Epub 2005 Mar 21].
17. Miyaki K., Takei I., Watanabe K., Nakashima H., Watanabe K., Omae K. Novel statistical classification model of type 2 diabetes mellitus patients for tailor-made prevention using data mining algorithm. J Epidemiol 2002, 12(3):243-248.
18. Averbook B.J., Fu P., Rao J.S., Mansour E.G. A long-term analysis of 1018 patients with melanoma by classic Cox regression and tree-structured survival analysis at a major referral center: iimplications on the future of cancer staging. Surgery 2002, 132(4):589-602. [discussion 602--4].
19. Valera V.A., Walter B.A., Yokoyama N., et al. Prognostic groups in colorectal carcinoma patients based on tumor cell proliferation and classification and regression tree (CART) survival analysis. Ann Surg Oncol 2007, 14(1):34-40. [Epub 2006 Oct 7].
20. Baquerizo A., Anselmo D., Shackleton C., et al. Phosphorus as an early predictive factor in patients with acute liver failure. Transplantation 2003, 75(12):2007-2014.
21. Bedossa P., Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR cooperative study group. Hepatology 1996, 24:289-293.
22. Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well?. Ann Intern Med 2004, 140(5):370-381.
23. Kau A., Vermehren J., Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008, 49(4):634-651. [Epub 2008 Jul 31].
24. Edelstein HA. Introduction to data mining and knowledge discovery. 1999 PotomacMD: Two Crows Corporation. 36p.
25. Han J., Kamber M. Data mining: concepts and techniques 2006, Morgan Kaufmann Publishers, San Fransisco San, CA, 550p.
26. Witten I.H., Frank E. Data mining: practical machine learning tools and techniques 2005, Morgan Kaufmann Publishers, San Francisco, CA, 525p.
27. Paul S., Piontkivska H. Discovery of novel targets for multi-epitope vaccines: screening of HIV-1 genomes using association rule mining. Retrovirology 2009, 6:62.
28. Kamal S.M., Nasser I.A. Hepatitis C genotype 4: what we know and what we don''t yet know. Hepatolgy 2008, 47(4):1371-1383.
29. Shiratori Y., Omata M. Predictors of the efficacy of interferon therapy for patients with chronic hepatitis C before and during therapy: how does this modify the treatment course?. J Gastroenterol Hepatol 2000, 15(Suppl.):E141-E151.
30. Izumi N., Asahina Y., Kurosaki M. Predictors of virological response to a combination therapy with pegylated interferon plus ribavirin including virus and host factors. Hepat Res Treat 2010, 2010:703602. [Epub 2010 Sep 5].
31. Manns M.P., McHutchison J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for intial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358(9286):958-965.
32. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347(13):975-982.
33. Kurosaki M., Sakamoto N., Iwasaki M., et al. Sequences in the interferon sensitivity-determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG-interferon plus ribavirin: data mining analysis. J Med Virol 2011, 83(3):445-452.
34. Males S., Gad R.R., Esmat G., et al. Serum alpha-foetoprotein level predicts treatment outcome in chronic hepatitis C. Antivir Ther 2007, 12(5):797-803.
35. Gad R.R., Males S., El Makhzangy H., et al. Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C. Liver Int 2008, 28(8):1112-1119. [Epub 2008 Apr 7].
36. Abdoul H., Mallet V., Pol S., Fontanet A. Serum alpha-fetoprotein predicts treatment outcome in chronic hepatitis C patients regardless of HCV genotype. PLoS One 2008, 3(6):e2391.
37. Sato Y., Nakata K., Kato Y., et al. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N Engl J Med 1993, 328(25):1802-1806.
38. Fattovich G., Giustina G., Degos F., et al. Morbidity and mortality in compensated cirrhosis type C. A retrospective follow-up study of 384 patients. Gastroenterology 1997, 112(2):463-472.
39. Hu K.Q., Kyulo N.L., Lim N., Elhazin B., Hillebrand D.J., Bock T. Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. Am J Gastroenterol 2004, 99(5):860-865.
40. Wilfredo Canchis P., Gonzalez S.A., Isabel Fiel M., et al. Hepatocyte proliferation in chronic hepatitis C: correlation with degree of liver disease and serum alpha-fetoprotein. Liver Int 2004, 24(3):198-203.
41. Di Bisceglie A.M., Sterling R.K., Chung R.T., et al. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol 2005, 43(3):434-441.
42. Murashima S., Tanaka M., Haramaki M., et al. A decrease in AFP level related to administration of interferon in patients with chronic hepatitis C and a high level of AFP. Dig Dis Sci 2006, 51(4):808-812.
43. Marcellin P., Asselah T., Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002, 36(5 Suppl.1):S47-S56.
44. Chen S.L., Morgan T.R. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006, 3(2):47-52. [Epub 2006 Apr 1].
45. Hansen N., Obel N., Christensen P.B., et al. Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: a Danish nationwide cohort study. BMC Infect Dis 2011, 11:177.
46. Mauss S., Hueppe D., John C., et al. Estimating the likelihood of sustained virological response in chronic hepatitis C therapy. J Viral Hepat 2011, 18(4):e81-e90.
47. Antonucci G., Longo M.A., Angeletti C., et al. The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65years. Am J Gastroenterol 2007, 102(7):1383-1391. [Epub 2007 Mar 31].